Valsts: Malta
Valoda: angļu
Klimata pārmaiņas: Medicines Authority
CETYLPYRIDINIUM CHLORIDE, GUAIFENESIN
Cupal Limited 103 - 105 Bath Road Slough, SL1 3UK, United Kingdom
R05DA09
CETYLPYRIDINIUM CHLORIDE 2.5 mg GUAIFENESIN 50 mg
ORAL LIQUID
CETYLPYRIDINIUM CHLORIDE 2.5 mg GUAIFENESIN 50 mg
OTC
COUGH AND COLD PREPARATIONS
Withdrawn
2007-07-12
Page 1 of 3 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF MEDICINAL PRODUCT Junior Meltus Chesty Coughs with Catarrh 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Guaiphenesin 50 mg Cetylpyridinium Chloride 2.5 mg 3. PHARMACEUTICAL FORM Oral Liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the symptomatic relief of coughs and catarrh associated with influenza, colds and mild throat infections. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION To be taken three to four times daily. _Children over 6 years_: Two 5 ml spoonfuls _Children 1-6 years_: One 5 ml spoonful _Children under 1 year_: Not recommended unless on medical advice. 4.3 CONTRAINDICATIONS This product is contraindicated in patients hypersensitive to any of the ingredients. 4.4 SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE Children under 1 year of age - this product should only be administered with medical advice. 4.5 INTERACTION WITH OTHER MEDICAMENTS AND OTHER FORMS OF INTERACTION Can cause transient abnormality in platelet aggregation patterns determined one hour after ingestion. 4.6 PREGNANCY AND LACTATION Although there are no known contra-indications, as with all medicines caution should be exercised when administering to pregnant or lactating women. 4.7 EFFECTS ON ABILITY TO DRIVE AND TO USE MACHINES Mild drowsiness has been reported. Page 2 of 3 4.8 UNDESIRABLE EFFECTS Some gastro-intestinal discomfort and mild drowsiness has been reported. Very large doses can cause nausea and vomiting. 4.9 OVERDOSE Very large doses may cause nausea and vomiting. It is however, rapidly metabolised and excreted in the urine. The patient should be kept under observation and treated symptomatically. 5. PHARMACOLOGICAL PROPERTIES 5.1 PHARMACODYNAMIC PROPERTIES A cou Izlasiet visu dokumentu